Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Xylitol and L-Carnitine PD Solutions (IPX15 and IPX07) in CAPD
NCT04001036Phase 2Terminated
- Sponsor
- Iperboreal Pharma
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of encoberminogene rezmadenovec in end stage renal disease (ESRD), sponsored by Iperboreal Pharma. Started Sep 2019; status: terminated.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT04001036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001036.